Phase I trial of fourth-generation chimeric antigen receptor T-cells targeting glypican-3 for advanced hepatocellular carcinoma.

Weijia Fang,Qihan Fu,Qingwei Zhao,Yi Zheng,Lulu Liu,Zonghai Li,Xiaomeng Dai,Huamao Wang,Xudong Zhu,Peng Zhao,Mei-Hua Lin,Hangyu Zhang,Jun Xiao,Jian Liu,Zhou Tong,Zhen Wang,Tingbo Liang

Phase I trial of fourth-generation chimeric antigen receptor T-cells targeting glypican-3 for advanced hepatocellular carcinoma.

2021

Weijia Fang
Qihan Fu
Qingwei Zhao
Yi Zheng
Lulu Liu
Zonghai Li
Xiaomeng Dai
Huamao Wang
Xudong Zhu
Peng Zhao
Mei-Hua Lin
Hangyu Zhang
Jun Xiao
Jian Liu
Zhou Tong
Zhen Wang
Tingbo Liang

4088Background: GPC3 is highly expressed in hepatocellular carcinoma (HCC) and is a promising target for HCC immunotherapy. Earlier phase I trial results demonstrated that second-generation GPC3-sp...

Keywords:

Hepatocellular carcinoma
Medicine
Glypican 3
Chimeric antigen receptor
fourth generation
Cancer research
Immunotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations